Answers are grounded in this paper and cite their sources.
Randomized trial assesses safety and pharmacokinetics of KH-001 in healthy men, suggesting rapid absorption and tolerability.
Introduction KH-001 besylate contains a novel small molecule developed for the on-demand treatment of premature ejaculation. It is a potent and selective serotonin reuptake transporter (SERT) inhibitor (IC50 of 6.6 nM) and a low-potency inhibitor of phosphodiesterase 4 (PDE4) isoforms. In preclinical studies using the para-chloramphetamine-induced ejaculation model in male Wistar rats, KH-001 significantly and dose-dependently prolonged ejaculation latency and reduced the proportion of ejaculating animals. Objective To assess first-in-human pharmacokinetics (PK), safety and tolerability of KH-001 besylate as an oral solution and orodispersible tablet (ODT) in healthy male volunteers. Methods A first-in-human randomised, placebo-controlled Phase 1 clinical study was conducted in 82 healthy men after UK regulatory authority (MHRA) and ethics committee approval in a certified phase 1 unit. Single ascending dose (SAD) cohorts (0.5 to 62.5 mg) received oral- KH-001 besylate. Pharmacokinetic sampling was performed over 24 hours post-dose for PK analysis of KH-001 and its primary metabolite KH-160 using a validated high performance liquid chromatography (HPLC) assay. Safety assessments included adverse events (AEs), vital signs, electrocardiograms (ECGs), mood evaluations, and routine safety blood panels. Additional SAD dose groups received 5 to 15 mg oral solution sublingually and 5 and 10 mg ODTs. Two multi-ascending dose (MAD) cohorts (each of 9 subjects) assessed repeat daily sublingual dosing for five consecutive days. Results Following oral dosing, KH-001 was reliably quantifiable only at 62.5 mg dose, indicating extensive first-pass metabolism after oral ingestion. KH-160 exposure increased proportionally with each dose, demonstrating exposure. In contrast, sublingual administration produced substantially higher systemic KH-001 exposure, rapid absorption with a time to maximum concentration (Tmax) of around 12-15 minutes, and complete clearance from the plasma within 4 hours consistent with on-demand therapeutic use. The ODT formulation showed similar pharmacokinetics. Importantly, no accumulation of KH-001 occurred with repeat sublingual dosing. Sublingual doses of 5-15 mg were generally well tolerated. Mild and transient AEs such as nausea and light-headedness occurred in a few subjects following sublingual application. No serious AEs or clinically relevant changes in safety parameters were observed. Conclusions KH-001 besylate, administered via the sublingual route, was safe and well tolerated, with only a few, mild, and transient AEs consistent with the hypothesized mechanism of action. Pharmacokinetic data demonstrated rapid systemic exposure and short duration via the sublingual route, with reduced levels of the primary metabolite KH-160, supporting this as the preferred route of administration. These findings support further clinical development activities of KH-001 besylate as an on-demand treatment in patients with premature ejaculation. Disclosure Yes, this is sponsored by industry/sponsor: Kadence Bio Ltd Clarification: Industry initiated, executed and funded study Any of the authors act as a consultant, employee or shareholder of an industry for: Kadence Bio Ltd
No takes yet. Share an insight, caveat, or question.
Gruss et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: